Skip to content
Open access

Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.

Aug 2026 · Clinical Cancer Research · pp. OF1-OF13 · 0 citations
Medicine

TL;DR

D dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab were tolerated and preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.

Abstract

Purpose

MEDI1191 is a lipid nanoparticle-formulated mRNA designed to induce local interleukin-12 production and intensify antitumor T cell responses. We report dose-escalation results from a first-in-human, open-label, phase I study of intratumoral MEDI1191 plus intravenous durvalumab (NCT03946800).

Methods

Patients were ≥18 years with advanced/metastatic solid tumors and had progressed on ≥1 line of prior therapy (immunotherapy permitted). Cutaneous/subcutaneous (Parts 1A and 1B) or deep-seated lesions (Part 1D) were injected; patients had ≥1 noninjected lesions measurable per RECIST v1.1. Target lesions were noninjected. MEDI1191 and durvalumab were given sequentially (Part 1A) or concurrently (Parts 1B and 1D). Primary objectives were safety and determination of maximum tolerated dose (MTD). Secondary objectives included efficacy.

Results

As of February 27, 2023, 61 patients were treated. Patients had a median of 4 prior regimens (range, 1-17); 39 (63.9%) received prior anti-PD-(L)1 immunotherapy. Treatment-emergent adverse events (TEAEs) occurred in 96.7% of patients and 41.0% experienced Grade 3/4 TEAEs. There were no dose-limiting toxicities. The MTD was not reached. Objective response rate was 9.8%, including 1 confirmed complete response and 5 confirmed partial responses (PRs). Duration of response was 2.7-22.3 months; median was not reached. Responses occurred in injected lesions, local noninjected lesions, and distant lesions. Three of the 39 patients with prior anti-PD-(L)1 therapy had PRs.

Conclusions

MEDI1191 and durvalumab were tolerated. Preliminary antitumor activity was encouraging in these heavily pretreated patients, including patients previously treated with immune checkpoint inhibitors.

Read PDF

Similar papers

Clinical trial Open access Sep 2026

Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors

Abstract Background SAR443216 is an engineered human trispecific antibody that targets human epidermal growth factor receptor 2 (HER2)-positive (HER2+) cancer cells and activates T cells via co-engagement of cluster of differentiation (CD)3 and CD28. This first-in-human, dose-escalation study evaluated the safety, effi...

E. Dumbrava, Do-Youn Oh, Min-Hee Ryu et al. · 0 citations
Open access Sep 2026

Autologous Glypican-3-Targeted, Armored CAR T Cells in Patients with Advanced Solid Tumors: A Phase 1 Dose-Escalation Study of TAK-102.

Findings support a manageable safety profile for TAK-102 and provide early evidence of biological activity in solid tumors, and are warranted to optimize dosing, improve CAR T-cell persistence, and evaluate efficacy in larger patient cohorts.

Y. Kuboki, T. Koyama, M. Ikeda et al. · 0 citations
Open access Oct 2026

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report here results from a phase I trial combining intratumoral injection of a CCL21-expressing dendritic cell (CCL21-DC) vaccine with pembrolizumab in patients with...

M. Oh, A. Lisberg, C. Dumitras et al. · 0 citations
Sep 2026

Abstract A003: Safety and efficacy of autologous tumor infiltrating lymphocyte therapy in pediatric and adolescent patients with immune checkpoint inhibitor-refractory metastatic melanoma: Results from a phase I clinical trial

Lifileucel is an autologous tumor infiltrating lymphocyte (TIL) therapy approved for adults with unresectable or metastatic melanoma previously treated with a PD-1 inhibitor and/or targeted therapy. Pediatric data have been lacking. We report preliminary safety, feasibility, and efficacy results from the melanoma...

S. Sait, J. Honeyman, S. Stapleton et al. · 0 citations
Clinical trial Open access Sep 2026

Neoadjuvant combined immunotherapy with intratumoral TransCon TLR7/8 Agonist and systemic TransCon IL-2 β/y or pembrolizumab in patients with locally advanced oral cancer—a monocentric experience

Neoadjuvant intratumoral TransCon TLR7/8 Agonist-based combination immunotherapy was feasible in this small prospective cohort of patients with locally advanced OSCC and was accompanied by consistent remodeling of the tumor immune microenvironment.

Manuel Weber, Leah Trumet, F. Lange et al. · 0 citations
Open access Aug 2026

A Phase 1 First-Time-in-Human, Open-Label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.

PURPOSE This first-in-human, nonrandomized, multicenter study investigated nelistotug (anti-CD96 monoclonal antibody [mAb]) as monotherapy (Arm A) and in combination with dostarlimab (anti-PD-1 mAb) (Arm B), and dostarlimab plus belrestotug (anti-TIGIT mAb) (Arm F) in patients with recurrent or advanced solid tumors....

L. Siu, Omid Hamid, Reva Schneider et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.